A Randomized Comparison of Two Prophylaxis Regimens and a Paired Comparison of On-demand and Prophylaxis Treatments in Hemophilia A Management

Overview

Journal J Thromb Haemost

Publisher Elsevier

Specialty Hematology

Date 2012 Jan 4

PMID 22212248

Citations 64

Authors

L A Valentino

V Mamonov

A Hellmann

D V Quon

A Chybicka

P Schroth

L Patrone

W-Y Wong

Affiliations

Soon will be listed here.

Abstract

Background: Prophylaxis with factor (F)VIII is considered the optimal treatment for managing hemophilia A patients without inhibitors.

Objectives: To compare the efficacy of two prophylaxis regimens (primary outcome) and of on-demand and prophylaxis treatments (secondary outcome), and to continue the evaluation of immunogenicity and overall safety of the ADVATE Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (rAHF-PFM).

Patients/methods: Previously on-demand-treated patients aged 7-59 years (n = 66) with FVIII levels ≤ 2% received 6 months of on-demand treatment and then were randomized to 12 months of either standard (20-40 IU kg(-1) every other day) or pharmacokinetic (PK)-tailored (20-80 IU kg(-1) every third day) prophylaxis, both regimens intended to maintain FVIII trough levels at or above 1%. Efficacy was evaluated in terms of annualized bleeding rates (ABRs). As subjects were first treated on-demand and then on prophylaxis, statistical comparisons between these treatments were paired.

Results: Twenty-two (33.3%) subjects on prophylaxis experienced no bleeding episodes, whereas none treated on-demand were free from an episode of bleeding. ABRs for the two prophylaxis regimens were comparable, whereas differences between on-demand and either prophylaxis were statistically significant (P < 0.0001): median (interquartile range [IQR]) ABRs were 43.9 (21.9), 1.0 (3.5), 2.0 (6.9) and 1.1 (4.9) during on-demand treatment, standard, PK-tailored and any prophylaxis, respectively. There were no differences in FVIII consumption or adverse event rates between prophylaxis regimens. No subject developed FVIII inhibitors.

Conclusions: The present study demonstrates comparable safety and effectiveness for two prophylaxis regimens and that prophylaxis significantly reduces bleeding compared with on-demand treatment. PK-tailored prophylaxis offers an alternative to standard prophylaxis for the prevention of bleeding.

Citing Articles

Efanesoctocog Alfa versus Standard and Extended Half-Life Factor VIII Prophylaxis in Adolescent and Adult Patients with Haemophilia A without Inhibitors.

Klamroth R, Kragh N, Arnaud A, Guyot P, Wilson A, Wojciechowski P Adv Ther. 2024; 42(1):427-441.

PMID: 39576433 PMC: 11782424. DOI: 10.1007/s12325-024-03032-3.

Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single-center experience in Bangladesh.

Tory S, Ghosh S, Nazneen H, Farhad N, Islam S, Hasan M EJHaem. 2024; 5(1):39-46.

PMID: 38406515 PMC: 10887364. DOI: 10.1002/jha2.832.

The effectiveness and safety of octocog alfa in patients with hemophilia A: up to 7-year follow-up of the real-world AHEAD international study.

Ozelo M, Hermans C, Carcao M, Guillet B, Gu J, Guerra R Ther Adv Hematol. 2024; 15:20406207231218624.

PMID: 38371314 PMC: 10874143. DOI: 10.1177/20406207231218624.

Bleeding pattern and consumption of factor VIII concentrate in adult patients with haemophilia A without inhibitors in the Czech Republic between 2013 and 2021 (Czech National Haemophilia Programme registry data).

Romanova G, Smejkal P, Ovesna P, Drbohlavova E, Dulicek P, Hajsmanova Z Ann Hematol. 2023; 102(11):3261-3270.

PMID: 37740066 PMC: 10567882. DOI: 10.1007/s00277-023-05453-6.

Barriers to prophylactic treatment among patients with haemophilia A in Shandong Province, China: a qualitative study.

Liu Z, Feng J, Fang Y, Cheng Y, Li S Orphanet J Rare Dis. 2023; 18(1):226.

PMID: 37537616 PMC: 10398971. DOI: 10.1186/s13023-023-02838-8.

References

Shapiro A, Gruppo R, Pabinger I, Collins P, Hay C, Schroth P . Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. Expert Opin Biol Ther. 2009; 9(3):273-83. DOI: 10.1517/14712590902729392. View

Manco-Johnson M, Abshire T, Shapiro A, Riske B, Hacker M, Kilcoyne R . Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357(6):535-44. DOI: 10.1056/NEJMoa067659. View

Nilsson I, Berntorp E, Lofqvist T, Pettersson H . Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992; 232(1):25-32. DOI: 10.1111/j.1365-2796.1992.tb00546.x. View

Collins P, Blanchette V, Fischer K, Bjorkman S, Oh M, Fritsch S . Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009; 7(3):413-20. DOI: 10.1111/j.1538-7836.2008.03270.x. View

Morado M, Villar A, Jimenez Yuste V, Quintana M, Hernandez Navarro F . Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia. 2005; 11(2):79-83. DOI: 10.1111/j.1365-2516.2005.00921.x. View

Royal S, Schramm W, Berntorp E, Giangrande P, Gringeri A, Ludlam C . Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia. 2002; 8(1):44-50. DOI: 10.1046/j.1365-2516.2002.00581.x. View

Tarantino M, Collins P, Hay C, Shapiro A, Gruppo R, Berntorp E . Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004; 10(5):428-37. DOI: 10.1111/j.1365-2516.2004.00932.x. View

Blanchette V, Shapiro A, Liesner R, Hernandez Navarro F, Warrier I, Schroth P . Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008; 6(8):1319-26. DOI: 10.1111/j.1538-7836.2008.03032.x. View

Hoots W, Nugent D . Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost. 2006; 96(4):433-40. DOI: 10.1160/th06-02-0125. View

10.

Lee M, Morfini M, Negrier C, Chamouard V . The pharmacokinetics of coagulation factors. Haemophilia. 2006; 12 Suppl 3:1-7. DOI: 10.1111/j.1365-2516.2006.01253.x. View

11.

Biss T, Chan A, Blanchette V, Iwenofu L, McLimont M, Carcao M . The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia. 2008; 14(5):923-30. DOI: 10.1111/j.1365-2516.2008.01810.x. View

12.

Iorio A, Marchesini E, Marcucci M, Stobart K, Chan A . Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev. 2011; (9):CD003429. DOI: 10.1002/14651858.CD003429.pub4. View

13.

Manco-Johnson M, Nuss R, Geraghty S, Funk S, Kilcoyne R . Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol. 1994; 47(2):113-7. DOI: 10.1002/ajh.2830470209. View

14.

Collins P, Bjorkman S, Fischer K, Blanchette V, Oh M, Schroth P . Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2009; 8(2):269-75. DOI: 10.1111/j.1538-7836.2009.03703.x. View

15.

Hacker M, Geraghty S, Manco-Johnson M . Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia. 2001; 7(4):392-6. DOI: 10.1046/j.1365-2516.2001.00534.x. View

16.

Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E . The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost. 1995; 73(2):247-51. View

17.

Lee C . Prevention of haemophilic synovitis: prophylaxis. Haemophilia. 2007; 13 Suppl 3:20-5. DOI: 10.1111/j.1365-2516.2007.01536.x. View

18.

Fischer K, van der Bom J, Molho P, Negrier C, Mauser-Bunschoten E, Roosendaal G . Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia. 2002; 8(6):745-52. DOI: 10.1046/j.1365-2516.2002.00695.x. View

19.

Lofqvist T, Nilsson I, Berntorp E, Pettersson H . Haemophilia prophylaxis in young patients--a long-term follow-up. J Intern Med. 1997; 241(5):395-400. DOI: 10.1046/j.1365-2796.1997.130135000.x. View

20.

Gouw S, van der Bom J, van den Berg H . Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007; 109(11):4648-54. DOI: 10.1182/blood-2006-11-056291. View